Assetmark Inc. Buys 15,399 Shares of Amgen Inc. (NASDAQ:AMGN)

Assetmark Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 293,970 shares of the medical research company's stock after purchasing an additional 15,399 shares during the period. Assetmark Inc. owned 0.05% of Amgen worth $76,620,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Capital Performance Advisors LLP bought a new stake in Amgen in the third quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the 3rd quarter worth about $29,000. Centricity Wealth Management LLC bought a new stake in shares of Amgen in the 4th quarter valued at about $25,000. Synergy Investment Management LLC acquired a new stake in shares of Amgen in the 4th quarter valued at approximately $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Amgen in the 4th quarter valued at approximately $36,000. Institutional investors own 76.50% of the company's stock.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. The trade was a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by company insiders.

Amgen Stock Up 1.4 %

NASDAQ AMGN traded up $4.38 during trading hours on Wednesday, hitting $316.57. 2,628,966 shares of the company traded hands, compared to its average volume of 2,544,250. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The business's 50-day moving average is $283.80 and its 200-day moving average is $299.78. The stock has a market capitalization of $170.06 billion, a price-to-earnings ratio of 41.93, a P/E/G ratio of 2.63 and a beta of 0.56. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.01%. Amgen's dividend payout ratio is presently 126.09%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on AMGN shares. Wolfe Research assumed coverage on shares of Amgen in a research note on Friday, November 15th. They issued a "peer perform" rating for the company. Bank of America boosted their price target on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday. Leerink Partners dropped their price objective on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $324.00 price target on shares of Amgen in a report on Friday, January 24th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $314.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.